Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clear-Brain: stimulating amyloid clearance in cerebral amyloid angiopathy
2023-506128-10-00Phase 2Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sodium oxybate in cerebral amyloid angiopathy (CAA) and familial cerebral amyloid angiopathy (3 arms), sponsored by Leiden University Medical Center. Primary endpoints: Morning CSF Aβ40 level change and Morning CSF Aβ42 level change. Planned start Apr 2024; status: authorised.
02
Drugs
sodium oxybate
03
Conditions
cerebral amyloid angiopathy (CAA)familial cerebral amyloid angiopathy
Beyond the preview
Go deeper on 2023-506128-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506128-10-00.